Literature DB >> 21485876

Nanoparticles containing nitric oxide donor with antileishmanial agent for synergistic effect against visceral leishmaniasis.

Sanket Pandya1, Rahul K Verma, Amit Misra.   

Abstract

Poly(lactide-co-glycolide) nanoparticles (NP) containing Doxorubicin (DOX) along with a nitric oxide (NO) donor Sodium Nitroprusside (SNP) were prepared by solvent displacement. NO is expected to synergise with antileishmanial activity of DOX. Preformulation studies showed no significant interaction between DOX and SNP. DOX and SNP loaded NP had an average size of 352 nm with 48% entrapment efficiency and a drug content of 10% w/w. Biphasic drug release was observed in vitro, with an initial burst of DOX and SNP (approximately 26% and 35% respectively) followed by sustained release for over 72 hrs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21485876     DOI: 10.1166/jbn.2011.1274

Source DB:  PubMed          Journal:  J Biomed Nanotechnol        ISSN: 1550-7033            Impact factor:   4.099


  2 in total

1.  Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells.

Authors:  Dinesh Vyas; Nicolas Lopez-Hisijos; Sulakshana Gandhi; M El-Dakdouki; Marc D Basson; Mary F Walsh; X Huang; Arpita K Vyas; Lakshmi S Chaturvedi
Journal:  J Nanosci Nanotechnol       Date:  2015-09

2.  Supplementation of host response by targeting nitric oxide to the macrophage cytosol is efficacious in the hamster model of visceral leishmaniasis and adds to efficacy of amphotericin B.

Authors:  Sanketkumar Pandya; Rahul Kumar Verma; Prashant Khare; Brajendra Tiwari; Dadi A Srinivasarao; Anuradha Dube; Neena Goyal; Amit Misra
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2016-01-14       Impact factor: 4.077

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.